DouxMatok raises $22 million Series B round that includes a number of strategic investors

June 20, 2019
CPG More...
“Better-for-You” Transformation More...
by Thomas Hayes
Very important

The round included participation from three strategics: Südzucker AG, DSM, and Singha. This funding comes about a year after DouxMatok (Lux Take: Positive) formed a manufacturing partnership with Südzucker AG. According to the press release, initial commercial quantities of DouxMatok sugar are expected to be available in Q4 2019, first targeting Europe and then North America. However, given that Singha (and BlueRed Partners) is now at the cap table, it appears Asia is also on the roadmap. Although DouxMatok is behind the schedule it announced in 2018, its technology is dominant in the sugar reduction space. Moreover, it is also now looking to use its platform for salt. Food and beverage clients should proceed to engage.

For the original news article, click here .

Further Reading

Stem goes public after completing SPAC merger

News Commentary | May 19, 2021

Stem completed its business combination with special‑purpose acquisition company (SPAC) Star Peak Energy Transition Corp. and became a publicly traded company on the New York Stock Exchange as of April 2021. After raising a total of more than $200 million in funding, Stem sought a buyer in early ... Not part of subscription

Amyris partners with Ingredion to bring its Reb M sweetener to B2B market

News Commentary | May 13, 2021

With an estimated transaction value of $100 million, Ingredion will get exclusive license to sell and market Amyris' Reb M sweetener technology under this agreement. Additionally, Ingredion will also get a minority stake in Amyris' new production facility in Brazil, to be completed by Q4 2021. ... Not part of subscription

Apeel raises $250 million Series E, bringing its valuation to more than $2 billion

News Commentary | August 19, 2021

Led by Temasek, this Series E funding round also had other prominent investors and brings Apeel's total funding to $635 million. This latest investment will allow Apeel to expand its supply chain reach and develop its recent technology acquisition based on hyperspectral imaging. Apeel's glycerolipid... Not part of subscription